Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Fecal Microbiota Transplantation (FMT) + Ipilimumab + Nivolumab & Renal Cell Carcinoma (RCC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

The open label phase I treatment trial NCT04163289 - PERFORM - Fecal Microbiota Transplantation (FMT) + Ipilimumab + Nivolumab & Renal Cell Carcinoma (RCC) revealed a favorable safety profile in unselected first-line metastatic renal cell carcinoma (1L mRCC) and shows promising clinical efficacy. Further prospective studies are needed to explore the changes in immune and microbiota profiles to identify biomarkers associated with healthier outcomes and reduced toxicities in patients undergoing immunotherapy (1).

References

(1) Fernandes et al. 2022 J Clin Oncol 40: suppl 16 abstr 4553

see also:
[Axitinib + Fecal Microbiota Transplantation (FMT) + Pembrolizumab & Renal Cell Carcinoma (RCC)](b…

References (Sources)

Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial).
Porcari et al. 2022 J Clin Oncol 40: suppl 6 abstr TPS407
Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study.
Fernandes et al. 2022 J Clin Oncol 40: suppl 16 abstr 4553

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!